<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31827422</article-id>
<article-id pub-id-type="pmc">6890831</article-id>
<article-id pub-id-type="doi">10.3389/fncel.2019.00524</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Hippocampal Synaptic Transmission and Plasticity: New Therapeutic Suggestions for Fragile X Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ciranna</surname>
<given-names>Lucia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/66446/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Costa</surname>
<given-names>Lara</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/217064/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Biomedical and Biotechnological Sciences, University of Catania</institution>, <addr-line>Catania</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Clinical and Experimental Medicine, University of Messina</institution>, <addr-line>Messina</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Annalisa Scimemi, University at Albany, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Andrea Tamas, University of Pécs, Hungary; Carmelo Sgobio, German Center for Neurodegenerative Diseases (DZNE), Germany</p>
</fn>
<corresp id="c001">*Correspondence: Lucia Ciranna, <email>ciranna@unict.it</email></corresp>
<fn fn-type="other" id="fn004">
<p>This article was submitted to Cellular Neurophysiology, a section of the journal Frontiers in Cellular Neuroscience</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>13</volume>
<elocation-id>524</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Ciranna and Costa.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Ciranna and Costa</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates glutamatergic synaptic transmission and plasticity in the hippocampus, a brain area with a key role in learning and memory. In agreement, several studies have demonstrated that PACAP modulates learning in physiological conditions. Recent publications show reduced PACAP levels and/or alterations in PACAP receptor expression in different conditions associated with cognitive disability. It is noteworthy that PACAP administration rescued impaired synaptic plasticity and learning in animal models of aging, Alzheimer’s disease, Parkinson’s disease, and Huntington’s chorea. In this context, results from our laboratory demonstrate that PACAP rescued metabotropic glutamate receptor-mediated synaptic plasticity in the hippocampus of a mouse model of fragile X syndrome (FXS), a genetic form of intellectual disability. PACAP is actively transported through the blood–brain barrier and reaches the brain following intranasal or intravenous administration. Besides, new studies have identified synthetic PACAP analog peptides with improved selectivity and pharmacokinetic properties with respect to the native peptide. Our review supports the shared idea that pharmacological activation of PACAP receptors might be beneficial for brain pathologies with cognitive disability. In addition, we suggest that the effects of PACAP treatment might be further studied as a possible therapy in FXS.</p>
</abstract>
<kwd-group>
<kwd>pituitary adenylate cyclase-activating polypeptide</kwd>
<kwd>fragile X syndrome</kwd>
<kwd>cyclic adenosine monophosphate</kwd>
<kwd>long-term depression induced by metabotropic glutamate receptor</kwd>
<kwd>hippocampus</kwd>
<kwd>learning</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Universitàdi Catania<named-content content-type="fundref-id">10.13039/501100004505</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="139"></ref-count>
<page-count count="10"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Pituitary adenylate cyclase-activating polypeptide (PACAP) was initially discovered in ovine hypothalamus as an endocrine regulator (<xref ref-type="bibr" rid="B91">Miyata et al., 1989</xref>). PACAP is highly expressed in the brain and in peripheral tissues in two forms of 38 and 27 amino acid residues, PACAP-38 and PACAP-27 (<xref ref-type="bibr" rid="B5">Arimura et al., 1991</xref>; <xref ref-type="bibr" rid="B75">Koves et al., 1991</xref>). In the present review, “PACAP” refers to PACAP-38, the most abundant form in the brain (<xref ref-type="bibr" rid="B5">Arimura et al., 1991</xref>; <xref ref-type="bibr" rid="B130">Vaudry et al., 2009</xref>). We will specifically indicate PACAP-38 and PACAP-27 to underline differences between the two forms.</p>
<p>Pituitary adenylate cyclase-activating polypeptide activates two main classes of G protein-coupled receptors: PAC1 and VPAC (<xref ref-type="bibr" rid="B130">Vaudry et al., 2009</xref>). PAC1 is PACAP specific, with a high nanomolar affinity for PACAP and a 1,000-fold lower affinity for the structurally related vasoactive intestinal peptide (VIP). VPAC receptors include VPAC1 and VPAC2 subtypes, with equally high nanomolar affinity for PACAP and VIP. PAC1 and VPAC receptors are expressed in peripheral tissues and in the central nervous system (CNS), where PAC1 is the most abundant (<xref ref-type="bibr" rid="B65">Jolivel et al., 2009</xref>). All PACAP/VIP receptors are positively coupled to adenylate cyclase; PAC1 receptors can also activate phospholipase C and Ca<sup>2+</sup> release. The brain localization, pharmacological features, signal transduction mechanisms, and biological effects of PACAP/VIP receptors are described in details in excellent reviews (<xref ref-type="bibr" rid="B34">Dickson and Finlayson, 2009</xref>; <xref ref-type="bibr" rid="B130">Vaudry et al., 2009</xref>; <xref ref-type="bibr" rid="B54">Harmar et al., 2012</xref>; <xref ref-type="bibr" rid="B58">Hirabayashi et al., 2018</xref>).</p>
<p>In the CNS, PACAP is a neurotrophic and a neuroprotective factor regulating differentiation of neuronal precursors, promoting neuronal survival, and exerting neuroprotective effects after brain damage (<xref ref-type="bibr" rid="B6">Arimura et al., 1994</xref>; <xref ref-type="bibr" rid="B120">Shioda and Nakamachi, 2015</xref>; <xref ref-type="bibr" rid="B103">Reglodi et al., 2018c</xref>). Acting on the brain, PACAP also regulates important physiological functions, among which are feeding (<xref ref-type="bibr" rid="B117">Sekar et al., 2017</xref>), circadian rhythm (<xref ref-type="bibr" rid="B59">Holland et al., 2018</xref>), body temperature (<xref ref-type="bibr" rid="B125">Tan et al., 2016</xref>), learning, and memory (see below). We will initially describe the physiological role of PACAP on learning and then highlight recent findings showing an involvement of PACAP in cognitive disability. Finally, we will discuss the possibility to use PACAP as a pharmacological tool in conditions of learning impairment.</p>
</sec>
<sec id="S2">
<title>Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Hippocampal Synaptic Transmission, Synaptic Plasticity, and Learning in Physiological Conditions</title>
<p>Pituitary adenylate cyclase-activating polypeptide receptors are highly expressed in rat hippocampus (<xref ref-type="bibr" rid="B121">Shioda et al., 1997</xref>; <xref ref-type="bibr" rid="B64">Jaworski and Proctor, 2000</xref>; <xref ref-type="bibr" rid="B66">Joo et al., 2004</xref>). On cultured hippocampal neurons, PACAP stimulated axon outgrowth (<xref ref-type="bibr" rid="B94">Ogata et al., 2015</xref>) and increased the size and density of dendritic spines (<xref ref-type="bibr" rid="B56">Hayata-Takano et al., 2019</xref>). Accordingly, PACAP-deficient mice displayed a reduced hippocampal spine density with respect to wild type (<xref ref-type="bibr" rid="B56">Hayata-Takano et al., 2019</xref>), indicating an important role of PACAP on synapse formation.</p>
<p>Pituitary adenylate cyclase-activating polypeptide increases the firing rate of hippocampal neurons (<xref ref-type="bibr" rid="B33">Di Mauro et al., 2003</xref>; <xref ref-type="bibr" rid="B79">Liu et al., 2003</xref>) and inhibits potassium currents responsible for membrane repolarization (<xref ref-type="bibr" rid="B126">Taylor et al., 2014</xref>; <xref ref-type="bibr" rid="B48">Gupte et al., 2015</xref>), which likely accounts for PACAP-induced increase in intrinsic excitability. Importantly, PACAP modulates hippocampal synaptic transmission and plasticity (<xref ref-type="bibr" rid="B136">Yang et al., 2010</xref>) and hippocampus-dependent learning (<xref ref-type="bibr" rid="B15">Borbely et al., 2013</xref>). In CA1 neurons, PACAP dose dependently modulates glutamate-mediated transmission (<xref ref-type="bibr" rid="B72">Kondo et al., 1997</xref>; <xref ref-type="bibr" rid="B109">Roberto et al., 2001</xref>; <xref ref-type="bibr" rid="B24">Ciranna and Cavallaro, 2003</xref>; <xref ref-type="bibr" rid="B123">Ster et al., 2009</xref>), exerting different effects on AMPA (<xref ref-type="bibr" rid="B26">Costa et al., 2009</xref>; <xref ref-type="bibr" rid="B127">Toda and Huganir, 2015</xref>) and NMDA receptor-mediated synaptic responses (<xref ref-type="bibr" rid="B135">Yaka et al., 2003</xref>; <xref ref-type="bibr" rid="B80">Macdonald et al., 2005</xref>). PACAP also stimulates acetylcholine release in the rodent hippocampus (<xref ref-type="bibr" rid="B83">Masuo et al., 1993</xref>), which in turn affects glutamate-mediated transmission (<xref ref-type="bibr" rid="B108">Roberto and Brunelli, 2000</xref>; <xref ref-type="bibr" rid="B109">Roberto et al., 2001</xref>; <xref ref-type="bibr" rid="B97">Pecoraro et al., 2017</xref>).</p>
<p>Pituitary adenylate cyclase-activating polypeptide-deficient mice show reduced long-term depression (LTP) in the dentate gyrus (<xref ref-type="bibr" rid="B84">Matsuyama et al., 2003</xref>) and impaired memory (<xref ref-type="bibr" rid="B3">Ago et al., 2013</xref>; <xref ref-type="bibr" rid="B124">Takuma et al., 2014</xref>). Impaired hippocampal LTP was also observed in PAC1 receptor-deficient mice (<xref ref-type="bibr" rid="B96">Otto et al., 2001</xref>; <xref ref-type="bibr" rid="B84">Matsuyama et al., 2003</xref>), together with a specific deficit in contextual fear conditioning, an index of associative memory, but not in Morris water maze test performance, indicative of spatial discrimination (<xref ref-type="bibr" rid="B114">Sauvage et al., 2000</xref>; <xref ref-type="bibr" rid="B96">Otto et al., 2001</xref>). In wild-type rats, intravenous injection of PACAP improved spatial memory (<xref ref-type="bibr" rid="B76">Ladjimi et al., 2019</xref>); direct infusion of PACAP in the hippocampus and amygdala improved learning in contextual fear conditioning (<xref ref-type="bibr" rid="B115">Schmidt et al., 2015</xref>); intracerebroventricular administration of PACAP exerted bi-directional effects (initial impairment and later improvement) on fear conditioning memory (<xref ref-type="bibr" rid="B89">Meloni et al., 2016</xref>, <xref ref-type="bibr" rid="B88">2018</xref>) and, at low doses, improved learning in passive avoidance response test (<xref ref-type="bibr" rid="B112">Sacchetti et al., 2001</xref>).</p>
</sec>
<sec id="S3">
<title>Dysregulation of Pituitary Adenylate Cyclase-Activating Polypeptide Functions in Conditions of Cognitive Impairment</title>
<p>Recent studies show reduced brain levels of PACAP and/or altered PACAP receptor expression in cognitive deficit (<xref ref-type="table" rid="T1">Table 1</xref>). PACAP-KO mice display neuronal apoptosis, oxidative damage, and neuroinflammation similar to those observed at old age; thus, PACAP deficiency has been proposed as a model of premature aging (<xref ref-type="bibr" rid="B102">Reglodi et al., 2018b</xref>). Accordingly, age-related cognition impairment was associated with reduced levels of PACAP in rhesus macaque brain (<xref ref-type="bibr" rid="B53">Han et al., 2017</xref>) and in an invertebrate model of aging, in which memory loss was rescued by activation of PAC1 receptors (<xref ref-type="bibr" rid="B98">Pirger et al., 2014</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Involvement of PACAP in conditions involving cognitive impairment.</p>
</caption>
<table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
<thead>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>Condition</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>Data from human patients</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>Data from animal models</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</td>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Aging</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Aged pond snail (<italic>Lymnaea stagnalis</italic>): low brain levels of PACAP. PACAP administration rescued learning impairment.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B98">Pirger et al., 2014</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">PACAP-KO mice: neuronal apoptosis, oxidative damage, and neuroinflammation.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B102">Reglodi et al., 2018b</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">Aged rhesus macaque: reduced brain levels of PACAP (striatum, parietal, and temporal lobes).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B53">Han et al., 2017</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Alzheimer’s disease (AD)</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">Transgenic AD mouse models: reduced PACAP gene expression.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B134">Wu et al., 2006</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">Transgenic AD mouse model: <italic>in vivo</italic> administration of PACAP exerted neuroprotective effects and improved learning.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B100">Rat et al., 2011</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">AD patients: reduced brain levels of PACAP.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B51">Han et al., 2014a</xref>, <xref ref-type="bibr" rid="B52">b</xref>, <xref ref-type="bibr" rid="B50">2015</xref></td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">Transgenic AD mouse model: reduced PACAP gene expression and brain levels. PACAP protected cultured neurons against Aβ toxicity.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B52">Han et al., 2014b</xref>, <xref ref-type="bibr" rid="B53">2017</xref></td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Parkinson’s disease (PD)</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="justify" colspan="1" rowspan="1" valign="top">6-OHDA-treated rats: <italic>in vivo</italic> administration of PACAP exerted neuroprotective effects and reduced behavioral deficits.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B104">Reglodi et al., 2004</xref>, <xref ref-type="bibr" rid="B106">2006</xref></td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">MPTP-treated mice: <italic>in vivo</italic> administration of PACAP exerted neuroprotective effects.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"><xref ref-type="bibr" rid="B132">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="B77">Lamine et al., 2016</xref>; <xref ref-type="bibr" rid="B78">Lamine-Ajili et al., 2016</xref></td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">MPTP-treated mice: <italic>in vivo</italic> administration of PACAP improved learning.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B31">Deguil et al., 2010</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">Prostaglandin J2-treated mice: PACAP-27 exerted neuroprotective effects.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B122">Shivers et al., 2014</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">MPTP-treated macaque: altered PAC1 receptor expression in basal ganglia</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B40">Feher et al., 2018</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Huntington’s disease (HD)</td>
<td align="justify" colspan="1" rowspan="1" valign="top">HD patients: reduced PAC1 receptor expression in the hippocampus.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Transgenic HD mouse models: reduced expression of PAC1, VPAC1, and VPAC2 receptors in the hippocampus. <italic>In vivo</italic> administration of PACAP rescued synapse formation, PAC1 receptor levels, and learning.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B19">Cabezas-Llobet et al., 2018</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Schizophrenia</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Schizophrenia patients: mutations of genes coding for PACAP and PAC1 receptors.</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B55">Hashimoto et al., 2007</xref>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Fragile X syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top">–</td>
<td align="justify" colspan="1" rowspan="1" valign="top"><italic>Fmr1</italic> KO mouse hippocampal slices: PACAP rescued abnormal synaptic plasticity.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B27">Costa et al., 2018</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib>
<italic>PACAP, pituitary adenylate cyclase-activating polypeptide; AD, Alzheimer’s disease; 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.</italic>
</attrib>
</table-wrap-foot>
</table-wrap>
<p>Defects in PACAP-mediated functions are well documented in Alzheimer’s disease (AD), the most devastating neurodegenerative disease leading to memory loss and dementia. Reduced PACAP levels were observed in the brain of different transgenic AD mouse models (<xref ref-type="bibr" rid="B134">Wu et al., 2006</xref>; <xref ref-type="bibr" rid="B52">Han et al., 2014b</xref>, <xref ref-type="bibr" rid="B53">2017</xref>) and in cortical brain samples from AD patients, where PACAP levels were inversely related to the amount of amyloid plaques and neurofibrillary tangle, as well as to dementia rating scores (<xref ref-type="bibr" rid="B51">Han et al., 2014a</xref>). Reduced PACAP levels and altered PAC1 receptor expression in the brain of AD patients were detected since early stages of the progressive neurodegeneration characterized by mild cognitive impairment (<xref ref-type="bibr" rid="B50">Han et al., 2015</xref>). Interestingly, besides exerting a neuroprotective role, PACAP stimulates a non-amyloidogenic processing pathway of amyloid precursor protein (APP) (<xref ref-type="bibr" rid="B71">Kojro et al., 2006</xref>), suggesting that PACAP might be used in AD therapy. Administration of PACAP has proven to be effective against Aβ-induced toxicity in different AD mouse models (<xref ref-type="bibr" rid="B100">Rat et al., 2011</xref>; <xref ref-type="bibr" rid="B52">Han et al., 2014b</xref>). Intranasal administration of PACAP to APP-transgenic mice increased brain expression of PACAP and PACAP receptors, stimulated the production of neurotrophic and antiapoptotic factors [brain-derived neurotrophic factor (BDNF) and Bcl-2], enhanced the expression of the Aβ-degrading enzyme neprilysin, and improved learning (<xref ref-type="bibr" rid="B100">Rat et al., 2011</xref>). Accordingly, VIP decreased amyloid plaques and prevented brain atrophy in the 5xFAD mouse model of AD (<xref ref-type="bibr" rid="B73">Korkmaz et al., 2018</xref>). The same authors suggest that VIP-mediated neuroprotective effects might also be used for therapy of Parkinson’s disease (PD) (<xref ref-type="bibr" rid="B74">Korkmaz and Tuncel, 2018</xref>).</p>
<p>Parkinson’s disease, a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, primarily affects motor control and also involves cognition deficit (<xref ref-type="bibr" rid="B1">Aarsland et al., 2017</xref>). A new study shows a decreased PAC1 receptor expression in basal ganglia in a macaque model of PD (<xref ref-type="bibr" rid="B40">Feher et al., 2018</xref>), suggesting that reduced PACAP function contributes to neurodegeneration and PACAP might become a promising tool for PD therapy (<xref ref-type="bibr" rid="B105">Reglodi et al., 2017</xref>). Administration of PACAP to rats treated with the neurotoxin 6-hydroxydopamine (6-OHDA), a model of PD, prevented degeneration of nigral dopaminergic neurons and rescued behavioral deficits (<xref ref-type="bibr" rid="B104">Reglodi et al., 2004</xref>, <xref ref-type="bibr" rid="B106">2006</xref>). Likewise, in a different murine PD model [mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)], intravenous injection of PACAP-27 prevented neuronal loss in the substantia nigra (<xref ref-type="bibr" rid="B132">Wang et al., 2008</xref>) and rescued learning deficit (<xref ref-type="bibr" rid="B31">Deguil et al., 2010</xref>). Still in MPTP-treated mice, PACAP treatment exerted neuroprotective effects in the substantia nigra (<xref ref-type="bibr" rid="B77">Lamine et al., 2016</xref>) and reduced abnormal autophagy, a mechanism that might contribute to neuronal death (<xref ref-type="bibr" rid="B78">Lamine-Ajili et al., 2016</xref>). PACAP-27 also prevented dopaminergic neuronal loss and motor deficit in prostaglandin J2-treated mice, another proposed PD model (<xref ref-type="bibr" rid="B122">Shivers et al., 2014</xref>).</p>
<p>A reduced expression of all PACAP receptor subtypes was observed in two different mouse models of Huntington’s disease (HD), an inherited degenerating motor and cognitive disease, and PAC1 receptors were downregulated in postmortem hippocampal samples from HD patients (<xref ref-type="bibr" rid="B19">Cabezas-Llobet et al., 2018</xref>). Remarkably, intranasal administration of PACAP to HD mice increased PAC1 receptor expression, stimulated BDNF production, reduced the formation of huntingtin aggregates, prevented the loss of hippocampal glutamatergic synapses, and improved memory (<xref ref-type="bibr" rid="B19">Cabezas-Llobet et al., 2018</xref>).</p>
<p>Finally, mutations of the genes coding for PACAP and for PAC1 receptors were found in schizophrenic patients together with reduced hippocampal volume and impaired memory (<xref ref-type="bibr" rid="B55">Hashimoto et al., 2007</xref>). Schizophrenia involves dysregulation of brain dopaminergic system (<xref ref-type="bibr" rid="B133">Weinstein et al., 2017</xref>). Interestingly, genetic ablation of D3 receptors increased the expression of PACAP and PACAP receptors in mouse hippocampus and enhanced memory (<xref ref-type="bibr" rid="B82">Marzagalli et al., 2016</xref>), suggesting a close interplay between PACAP and dopamine on learning and memory.</p>
</sec>
<sec id="S4">
<title>Pituitary Adenylate Cyclase-Activating Polypeptide Rescues Synaptic Plasticity in a Mouse Model of Fragile X Syndrome</title>
<p>Fragile X syndrome (FXS) is a genetic form of intellectual disability affecting 1/4,000 males and 1/6,000 females. FXS patients show cognitive and language deficits; subgroups of patients also display autistic features, epilepsy, attention deficit and hyperactivity disorder (ADHD), and mood disorders (<xref ref-type="bibr" rid="B10">Bardoni et al., 2006</xref>; <xref ref-type="bibr" rid="B87">Maurin et al., 2014</xref>; <xref ref-type="bibr" rid="B46">Gross et al., 2015</xref>; <xref ref-type="bibr" rid="B49">Hagerman et al., 2017</xref>). FXS is caused by transcriptional silencing of the FMR1 gene coding for fragile X mental retardation protein (FMRP) (<xref ref-type="bibr" rid="B131">Verkerk et al., 1991</xref>), an mRNA-binding protein mostly functioning as a repressor (<xref ref-type="bibr" rid="B41">Garber et al., 2006</xref>) and in some cases as an enhancer (<xref ref-type="bibr" rid="B14">Bechara et al., 2009</xref>) of protein translation (<xref ref-type="bibr" rid="B30">Darnell and Klann, 2013</xref>). Hundreds of mRNAs have been identified as FMRP targets, particularly mRNAs coding for proteins involved in synapse development and function (<xref ref-type="bibr" rid="B11">Bassell and Warren, 2008</xref>; <xref ref-type="bibr" rid="B12">Bear et al., 2008</xref>). Cortical neurons from <italic>Fmr1</italic> knock out (<italic>Fmr1</italic> KO) animal models of FXS (<xref ref-type="bibr" rid="B25">Comery et al., 1997</xref>) and FXS patients (<xref ref-type="bibr" rid="B62">Irwin et al., 2000</xref>) display an increased density of dendritic spines, with a long and thin morphology reminiscent of immature filopodia. Abnormal dendritic spine morphology has crucial consequences on synaptic function. Many alterations of glutamate-mediated synaptic transmission and plasticity were found in the brain of <italic>Fmr1</italic> KO mice. Among the first discovered, hippocampal LTP induced by metabotropic glutamate receptors (mGluR-LTD) is abnormally enhanced (<xref ref-type="bibr" rid="B60">Huber et al., 2002</xref>). Exaggerated mGluR-LTD led to formulation of the “mGluR theory” of FXS, pointing out excessive signaling downstream activation of mGluRs (<xref ref-type="bibr" rid="B13">Bear et al., 2004</xref>). In <italic>Fmr1</italic> KO neurons, mGluRs also show altered cell-surface mobility, abnormal coupling to NMDA receptors, and impaired mGluR-LTD of NMDA-mediated synaptic currents (<xref ref-type="bibr" rid="B4">Aloisi et al., 2017</xref>). Other malfunctions of glutamatergic synapses in <italic>Fmr1</italic> KO mouse brain include a reduced coupling of mGluRs to Homer proteins (<xref ref-type="bibr" rid="B44">Giuffrida et al., 2005</xref>), a reduced NMDA/AMPA ratio (<xref ref-type="bibr" rid="B139">Yun and Trommer, 2011</xref>; <xref ref-type="bibr" rid="B45">Gocel and Larson, 2012</xref>; <xref ref-type="bibr" rid="B4">Aloisi et al., 2017</xref>), and altered NMDA-dependent plasticity (<xref ref-type="bibr" rid="B129">Uzunova et al., 2014</xref>; <xref ref-type="bibr" rid="B16">Bostrom et al., 2015</xref>). An increased expression of Ca<sup>2+</sup>-permeable AMPA receptors was recently found in human neural precursors derived from FXS patients (<xref ref-type="bibr" rid="B2">Achuta et al., 2018</xref>). Inhibitory synapses are also affected in the brain of FXS animal models, with a deficit of GABAergic inhibition (<xref ref-type="bibr" rid="B81">Martin et al., 2014</xref>; <xref ref-type="bibr" rid="B18">Braat and Kooy, 2015</xref>) and abnormal functioning of GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="B57">He et al., 2014</xref>).</p>
<p>At a cellular level, FMRP absence is associated with dysregulation of many signaling pathways, among which upregulation of PI3K/Akt/mTOR pathway (<xref ref-type="bibr" rid="B119">Sharma et al., 2010</xref>; <xref ref-type="bibr" rid="B61">Huber et al., 2015</xref>), overactivation of GSK3 (<xref ref-type="bibr" rid="B90">Min et al., 2009</xref>), and altered MAPK/ERK signaling (<xref ref-type="bibr" rid="B69">Kim et al., 2008</xref>; <xref ref-type="bibr" rid="B95">Osterweil et al., 2010</xref>). The large amount of data now available on the molecular basis of FXS provides several cues for a possible therapy of FXS, currently under investigation (<xref ref-type="bibr" rid="B113">Santoro et al., 2012</xref>; <xref ref-type="bibr" rid="B118">Sethna et al., 2014</xref>; <xref ref-type="bibr" rid="B46">Gross et al., 2015</xref>; <xref ref-type="bibr" rid="B20">Castagnola et al., 2017</xref>). Each proposed strategy might be useful in subsets of FXS patients, owing to a large individual heterogeneity with respect to the type and severity of symptoms (<xref ref-type="bibr" rid="B63">Jacquemont et al., 2014</xref>).</p>
<p>Interestingly, early observations on FXS patients and latest findings on FXS animal models have pointed out a downregulation of the cyclic adenosine monophosphate (cAMP) pathway, originating a “cAMP theory” of FXS (<xref ref-type="bibr" rid="B67">Kelley et al., 2008</xref>). A recent study shows that the mRNA coding for phosphodiesterase 2A (PDE2A), a cAMP-degrading enzyme, is among the most prominent targets of FMRP (<xref ref-type="bibr" rid="B85">Maurin et al., 2018a</xref>). In the brain of <italic>Fmr1</italic> KO mice, PDE2A is overexpressed and overactive, causing reduced cAMP formation and dysregulation of cAMP downstream signaling (<xref ref-type="bibr" rid="B86">Maurin et al., 2018b</xref>). In line with this, synaptic plasticity, learning, and behavior in <italic>Fmr1</italic> KO mice are rescued by agonists of serotonin 5-HT<sub>7</sub> receptors, positively coupled to adenylate cyclase (<xref ref-type="bibr" rid="B29">Costa et al., 2012</xref>, <xref ref-type="bibr" rid="B28">2015</xref>, <xref ref-type="bibr" rid="B27">2018</xref>; <xref ref-type="bibr" rid="B23">Ciranna and Catania, 2014</xref>), by PDE4 inhibitors (<xref ref-type="bibr" rid="B22">Choi et al., 2015</xref>, <xref ref-type="bibr" rid="B21">2016</xref>), and by a selective PDE2A inhibitor (<xref ref-type="bibr" rid="B86">Maurin et al., 2018b</xref>). Of note, inhibition of PDE2A also corrected abnormal dendritic spine morphology of cortical neurons from <italic>Fmr1</italic> KO mice (<xref ref-type="bibr" rid="B86">Maurin et al., 2018b</xref>). All these data confirm a deficit in cAMP-mediated signaling in <italic>Fmr1</italic> KO neurons and demonstrate that pharmacological manipulations increasing cAMP levels can rescue synaptic morphology and function, learning, and behavior in animal models of FXS.</p>
<p>Pituitary adenylate cyclase activating polypeptide is a potent stimulator of adenylate cyclase activity (<xref ref-type="bibr" rid="B91">Miyata et al., 1989</xref>; <xref ref-type="bibr" rid="B130">Vaudry et al., 2009</xref>). Consistent with the cAMP hypothesis of FXS, we found that PACAP reversed mGluR-LTD in the CA3-CA1 hippocampal synapse in wild-type mice and reduced exaggerated mGluR-LTD in <italic>Fmr1</italic> KO, thus correcting a synaptic defect typically observed in FXS mouse models (<xref ref-type="bibr" rid="B27">Costa et al., 2018</xref>). This result offers novel suggestions for a possible therapy of FXS, for which no specific cure is presently available. In future studies, it would be interesting to test if PACAP can correct other abnormal features in <italic>Fmr1</italic> KO neurons (dendrite development, synapse formation and function, ion channel expression, membrane excitability, and intracellular signaling) and rescue learning and behavior when administered <italic>in vivo</italic> to <italic>Fmr1</italic> KO mice.</p>
<p>Dysregulation of cyclic nucleotide pathways was found at different levels (synthesis, functioning, and/or degradation by PDE) in aging and age-related cognitive decline (<xref ref-type="bibr" rid="B68">Kelly, 2018</xref>). Accordingly, inhibition of PDE activity improved memory in animal models of AD (<xref ref-type="bibr" rid="B47">Gulisano et al., 2018</xref>) and HD (<xref ref-type="bibr" rid="B111">Saavedra et al., 2013</xref>) and seems to prevent memory loss in elderly humans and in AD patients (<xref ref-type="bibr" rid="B99">Prickaerts et al., 2017</xref>). As indicated above, in FXS, the cAMP pathway is also dysregulated, and increasing cAMP rescues several phenotypes. Therefore, altered cAMP signaling might be a common feature in cognitive deficits of very different origin, in which administration of PACAP might be beneficial.</p>
</sec>
<sec id="S5">
<title>Systemic Administration Routes for Effective Brain Delivery of Pituitary Adenylate Cyclase-Activating Polypeptide</title>
<p>Pituitary adenylate cyclase activating polypeptide-38 is actively transported into the brain across the blood–brain barrier (BBB) by a saturable carrier, whereas PACAP-27 passes the BBB by transmembrane diffusion (<xref ref-type="bibr" rid="B8">Banks et al., 1993</xref>). After intravenous administration, the amount of PACAP-38 brain uptake was high enough to exert neuroprotective effects (<xref ref-type="bibr" rid="B9">Banks et al., 1996</xref>). The rate of PACAP-38 transport varies largely in different brain areas, with maximal uptake in the hypothalamus and in the hippocampus (<xref ref-type="bibr" rid="B92">Nonaka et al., 2002</xref>), and can be altered in pathological conditions (<xref ref-type="bibr" rid="B7">Banks et al., 1998</xref>; <xref ref-type="bibr" rid="B92">Nonaka et al., 2002</xref>; <xref ref-type="bibr" rid="B107">Rhea et al., 2018</xref>).</p>
<p>On the other side, PACAP-38 and PACAP-27 are transported out of the brain by a common efflux mechanism, reducing their brain levels (<xref ref-type="bibr" rid="B8">Banks et al., 1993</xref>). It is noteworthy that antisense inhibition of peptide transport system-6 (PTS-6) improved brain uptake and neuroprotective effects of PACAP-27 in murine models of AD and stroke (<xref ref-type="bibr" rid="B37">Dogrukol-Ak et al., 2009</xref>), suggesting that inhibition of PTS-6 efflux component might become a therapeutic strategy to enhance central effects of PACAP.</p>
<p>Some issues were raised about intravenous administration of PACAP to humans: PACAP-38 induced headache in healthy and migraine-suffering subjects (<xref ref-type="bibr" rid="B116">Schytz et al., 2009</xref>). Headache was also reported after intravenous infusion of PACAP-27 to healthy subjects (<xref ref-type="bibr" rid="B42">Ghanizada et al., 2019a</xref>) and migraine patients (<xref ref-type="bibr" rid="B43">Ghanizada et al., 2019b</xref>).</p>
<p>Other issues against intravenous administration of PACAP concern metabolic stability and selectivity. In fact, PACAP-38 showed a very short half-life (&lt;5 min) in human plasma <italic>in vitro</italic>, being converted by the blood enzyme dipeptidyl peptidase IV into shorter peptides that behave as PACAP receptor antagonists, whereas PACAP-27 was relatively stable (<xref ref-type="bibr" rid="B17">Bourgault et al., 2008</xref>).</p>
<p>Besides, parenteral administration of PACAP can induce undesired peripheral actions, among which are cardiovascular (<xref ref-type="bibr" rid="B110">Runcie et al., 1995</xref>; <xref ref-type="bibr" rid="B39">Farnham et al., 2012</xref>) and hormonal effects (<xref ref-type="bibr" rid="B128">Tsutsumi et al., 2002</xref>). To overcome these limitations, new synthetic agonists of PACAP receptors have been developed with improved metabolic stability, higher brain uptake, selectivity for PAC1 receptors (the predominant PACAP receptors in the CNS), and reduced side effects (<xref ref-type="bibr" rid="B17">Bourgault et al., 2008</xref>; <xref ref-type="bibr" rid="B32">Dejda et al., 2011</xref>; <xref ref-type="bibr" rid="B35">Doan et al., 2011</xref>; <xref ref-type="bibr" rid="B77">Lamine et al., 2016</xref>).</p>
<p>Another strategy exploits conjugation of PACAP with a TAT peptide, improving passage through the BBB (<xref ref-type="bibr" rid="B137">Yu et al., 2012a</xref>, <xref ref-type="bibr" rid="B138">b</xref>). Carrier vesicles can also be used to protect peptides from blood-degrading enzymes (<xref ref-type="bibr" rid="B38">Dufes et al., 2004</xref>).</p>
<p>Administration routes for brain delivery of PACAP are illustrated in details in a recent review (<xref ref-type="bibr" rid="B101">Reglodi et al., 2018a</xref>). A promising non-invasive and easy route is intranasal application, by which PACAP reaches the brain fast and effectively in rodents, exerting neuroprotective effects in mouse models of AD (<xref ref-type="bibr" rid="B100">Rat et al., 2011</xref>; <xref ref-type="bibr" rid="B93">Nonaka et al., 2012</xref>) and HD (<xref ref-type="bibr" rid="B19">Cabezas-Llobet et al., 2018</xref>). Intranasal administration of PACAP was also tested on human volunteers, showing good safety and tolerability (<xref ref-type="bibr" rid="B36">Doberer et al., 2007</xref>; <xref ref-type="bibr" rid="B101">Reglodi et al., 2018a</xref>) with only mild local adverse reactions (<xref ref-type="bibr" rid="B70">Kinhult et al., 2003</xref>). Interestingly, headache was not reported after intranasal application of PACAP-38 (<xref ref-type="bibr" rid="B36">Doberer et al., 2007</xref>), suggesting this route as a valuable alternative to intravenous administration.</p>
</sec>
<sec id="S6">
<title>Concluding Remarks</title>
<p>Pituitary adenylate cyclase activating polypeptide plays an important role in learning and has a therapeutic potential in cognition deficits associated with disruption of cyclic nucleotide signaling. We suggest that the effects of PACAP might also be studied for a possible therapy of FXS, in which a deficit in cAMP formation and downstream signaling were evidenced. For future translational applications, it would be interesting to test <italic>in vivo</italic> effects of PACAP on learning and behavioral deficits in FXS animal models.</p>
<p>Pituitary adenylate cyclase activating polypeptide is brain permeant and has already proved to be safe on healthy humans and thus might be tested in clinical trials. To improve PACAP brain uptake, it would be worth focusing on new selective PAC1 receptor agonists with enhanced metabolic stability, on delivery carriers, and/or on suitable administration routes.</p>
</sec>
<sec id="S7">
<title>Author Contributions</title>
<p>LCi designed and directed the research projects and wrote the manuscript. LCo performed the experiments and data analysis, and contributed to the manuscript preparation.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> The present work was financed by Telethon Foundation (grant GGP13145) and by Università di Catania, Italy (grant Chance 2017).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Creese</surname><given-names>B.</given-names></name><name><surname>Politis</surname><given-names>M.</given-names></name><name><surname>Chaudhuri</surname><given-names>K. R.</given-names></name><name><surname>Ffytche</surname><given-names>D. H.</given-names></name><name><surname>Weintraub</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Cognitive decline in Parkinson disease.</article-title>
<source/><italic>Nat. Rev. Neurol.</italic>
<volume>13</volume>
<fpage>217</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.27</pub-id>
<pub-id pub-id-type="pmid">28257128</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achuta</surname><given-names>V. S.</given-names></name><name><surname>Moykkynen</surname><given-names>T.</given-names></name><name><surname>Peteri</surname><given-names>U. K.</given-names></name><name><surname>Turconi</surname><given-names>G.</given-names></name><name><surname>Rivera</surname><given-names>C.</given-names></name><name><surname>Keinanen</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Functional changes of AMPA responses in human induced pluripotent stem cell-derived neural progenitors in fragile X syndrome.</article-title>
<source/><italic>Sci. Signal</italic>
<volume>11</volume>:<issue>eaan8784</issue>. <pub-id pub-id-type="doi">10.1126/scisignal.aan8784</pub-id>
<pub-id pub-id-type="pmid">29339535</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ago</surname><given-names>Y.</given-names></name><name><surname>Hiramatsu</surname><given-names>N.</given-names></name><name><surname>Ishihama</surname><given-names>T.</given-names></name><name><surname>Hazama</surname><given-names>K.</given-names></name><name><surname>Hayata-Takano</surname><given-names>A.</given-names></name><name><surname>Shibasaki</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>24</volume>
<fpage>74</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0b013e32835cf3e5</pub-id>
<pub-id pub-id-type="pmid">23268987</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloisi</surname><given-names>E.</given-names></name><name><surname>Le Corf</surname><given-names>K.</given-names></name><name><surname>Dupuis</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Ginger</surname><given-names>M.</given-names></name><name><surname>Labrousse</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>8</volume>:<issue>1103</issue>. <pub-id pub-id-type="doi">10.1038/s41467-017-01191-2</pub-id>
<pub-id pub-id-type="pmid">29062097</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A.</given-names></name><name><surname>Miyata</surname><given-names>A.</given-names></name><name><surname>Mizuno</surname><given-names>K.</given-names></name><name><surname>Coy</surname><given-names>D. H.</given-names></name><name><surname>Kitada</surname><given-names>C.</given-names></name></person-group> (<year>1991</year>). <article-title>Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes.</article-title>
<source/><italic>Endocrinology</italic>
<volume>129</volume>
<fpage>2787</fpage>–<lpage>2789</lpage>. <pub-id pub-id-type="doi">10.1210/endo-129-5-2787</pub-id>
<pub-id pub-id-type="pmid">1935809</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A.</given-names></name><name><surname>Weill</surname><given-names>C.</given-names></name><name><surname>Fiore</surname><given-names>R. C.</given-names></name><name><surname>Tatsuno</surname><given-names>I.</given-names></name><name><surname>Bay</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>1994</year>). <article-title>PACAP functions as a neurotrophic factor.</article-title>
<source/><italic>Ann. N. Y. Acad. Sci.</italic>
<volume>739</volume>
<fpage>228</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1994.tb19825.x</pub-id>
<pub-id pub-id-type="pmid">7726997</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Kastin</surname><given-names>A. J.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>151</volume>
<fpage>116</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.1998.6786</pub-id>
<pub-id pub-id-type="pmid">9582259</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Kastin</surname><given-names>A. J.</given-names></name><name><surname>Komaki</surname><given-names>G.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name></person-group> (<year>1993</year>). <article-title>Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>267</volume>
<fpage>690</fpage>–<lpage>696</lpage>. <pub-id pub-id-type="pmid">8246142</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Uchida</surname><given-names>D.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A.</given-names></name><name><surname>Shioda</surname><given-names>S.</given-names></name></person-group> (<year>1996</year>). <article-title>Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons.</article-title>
<source/><italic>Ann. N. Y. Acad. Sci.</italic>
<volume>805</volume>
<fpage>270</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1996.tb17489.x</pub-id>
<pub-id pub-id-type="pmid">8993409</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardoni</surname><given-names>B.</given-names></name><name><surname>Davidovic</surname><given-names>L.</given-names></name><name><surname>Bensaid</surname><given-names>M.</given-names></name><name><surname>Khandjian</surname><given-names>E. W.</given-names></name></person-group> (<year>2006</year>). <article-title>The fragile X syndrome: exploring its molecular basis and seeking a treatment.</article-title>
<source/><italic>Expert Rev. Mol. Med.</italic>
<volume>8</volume>
<fpage>1</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1017/s1462399406010751</pub-id>
<pub-id pub-id-type="pmid">16626504</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassell</surname><given-names>G. J.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.</article-title>
<source/><italic>Neuron</italic>
<volume>60</volume>
<fpage>201</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.10.004</pub-id>
<pub-id pub-id-type="pmid">18957214</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bear</surname><given-names>M. F.</given-names></name><name><surname>Dolen</surname><given-names>G.</given-names></name><name><surname>Osterweil</surname><given-names>E.</given-names></name><name><surname>Nagarajan</surname><given-names>N.</given-names></name></person-group> (<year>2008</year>). <article-title>Fragile X: translation in action.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>33</volume>
<fpage>84</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301610</pub-id>
<pub-id pub-id-type="pmid">17940551</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bear</surname><given-names>M. F.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2004</year>). <article-title>The mGluR theory of fragile X mental retardation.</article-title>
<source/><italic>Trends Neurosci.</italic>
<volume>27</volume>
<fpage>370</fpage>–<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2004.04.009</pub-id>
<pub-id pub-id-type="pmid">15219735</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechara</surname><given-names>E. G.</given-names></name><name><surname>Didiot</surname><given-names>M. C.</given-names></name><name><surname>Melko</surname><given-names>M.</given-names></name><name><surname>Davidovic</surname><given-names>L.</given-names></name><name><surname>Bensaid</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>A novel function for fragile X mental retardation protein in translational activation.</article-title>
<source/><italic>PLoS Biol.</italic>
<volume>7</volume>:<issue>e16</issue>. <pub-id pub-id-type="doi">10.1371/journal.pbio.1000016</pub-id>
<pub-id pub-id-type="pmid">19166269</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borbely</surname><given-names>E.</given-names></name><name><surname>Scheich</surname><given-names>B.</given-names></name><name><surname>Helyes</surname><given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuropeptides in learning and memory.</article-title>
<source/><italic>Neuropeptides</italic>
<volume>47</volume>
<fpage>439</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2013.10.012</pub-id>
<pub-id pub-id-type="pmid">24210137</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostrom</surname><given-names>C. A.</given-names></name><name><surname>Majaess</surname><given-names>N. M.</given-names></name><name><surname>Morch</surname><given-names>K.</given-names></name><name><surname>White</surname><given-names>E.</given-names></name><name><surname>Eadie</surname><given-names>B. D.</given-names></name><name><surname>Christie</surname><given-names>B. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Rescue of NMDAR-dependent synaptic plasticity in fmr1 knock-out mice.</article-title>
<source/><italic>Cereb. Cortex</italic>
<volume>25</volume>
<fpage>271</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bht237</pub-id>
<pub-id pub-id-type="pmid">23968838</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgault</surname><given-names>S.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><name><surname>Botia</surname><given-names>B.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name><name><surname>Vaudry</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Novel stable PACAP analogs with potent activity towards the PAC1 receptor.</article-title>
<source/><italic>Peptides</italic>
<volume>29</volume>
<fpage>919</fpage>–<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2008.01.022</pub-id>
<pub-id pub-id-type="pmid">18353507</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname><given-names>S.</given-names></name><name><surname>Kooy</surname><given-names>R. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>88</volume>
<fpage>48</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.06.028</pub-id>
<pub-id pub-id-type="pmid">25016041</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas-Llobet</surname><given-names>N.</given-names></name><name><surname>Vidal-Sancho</surname><given-names>L.</given-names></name><name><surname>Masana</surname><given-names>M.</given-names></name><name><surname>Fournier</surname><given-names>A.</given-names></name><name><surname>Alberch</surname><given-names>J.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide (PACAP) enhances hippocampal synaptic plasticity and improves memory performance in Huntington’s Disease.</article-title>
<source/><italic>Mol. Neurobiol</italic>.
<volume>55</volume>
<fpage>8263</fpage>–<lpage>8277</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-018-0972-5</pub-id>
<pub-id pub-id-type="pmid">29526016</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castagnola</surname><given-names>S.</given-names></name><name><surname>Bardoni</surname><given-names>B.</given-names></name><name><surname>Maurin</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>The search for an effective therapy to treat fragile X syndrome: dream or reality?</article-title>
<source/><italic>Front. Synaptic Neurosci.</italic>
<volume>9</volume>:<issue>15</issue>. <pub-id pub-id-type="doi">10.3389/fnsyn.2017.00015</pub-id>
<pub-id pub-id-type="pmid">29163124</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>C. H.</given-names></name><name><surname>Schoenfeld</surname><given-names>B. P.</given-names></name><name><surname>Bell</surname><given-names>A. J.</given-names></name><name><surname>Hinchey</surname><given-names>J.</given-names></name><name><surname>Rosenfelt</surname><given-names>C.</given-names></name><name><surname>Gertner</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Multiple drug treatments that increase cAMP signaling restore long-term memory and aberrant signaling in fragile X syndrome models.</article-title>
<source/><italic>Front. Behav. Neurosci.</italic>
<volume>10</volume>:<issue>136</issue>. <pub-id pub-id-type="doi">10.3389/fnbeh.2016.00136</pub-id>
<pub-id pub-id-type="pmid">27445731</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>C. H.</given-names></name><name><surname>Schoenfeld</surname><given-names>B. P.</given-names></name><name><surname>Weisz</surname><given-names>E. D.</given-names></name><name><surname>Bell</surname><given-names>A. J.</given-names></name><name><surname>Chambers</surname><given-names>D. B.</given-names></name><name><surname>Hinchey</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>PDE-4 inhibition rescues aberrant synaptic plasticity in drosophila and mouse models of fragile X syndrome.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>35</volume>
<fpage>396</fpage>–<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1356-12.2015</pub-id>
<pub-id pub-id-type="pmid">25568131</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciranna</surname><given-names>L.</given-names></name><name><surname>Catania</surname><given-names>M. V.</given-names></name></person-group> (<year>2014</year>). <article-title>5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>8</volume>:<issue>250</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00250</pub-id>
<pub-id pub-id-type="pmid">25221471</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciranna</surname><given-names>L.</given-names></name><name><surname>Cavallaro</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>184</volume>
<fpage>778</fpage>–<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1016/s0014-4886(03)00300-5</pub-id>
<pub-id pub-id-type="pmid">14769370</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comery</surname><given-names>T. A.</given-names></name><name><surname>Harris</surname><given-names>J. B.</given-names></name><name><surname>Willems</surname><given-names>P. J.</given-names></name><name><surname>Oostra</surname><given-names>B. A.</given-names></name><name><surname>Irwin</surname><given-names>S. A.</given-names></name><name><surname>Weiler</surname><given-names>I. J.</given-names></name><etal></etal></person-group> (<year>1997</year>). <article-title>Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>94</volume>
<fpage>5401</fpage>–<lpage>5404</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.10.5401</pub-id>
<pub-id pub-id-type="pmid">9144249</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>L.</given-names></name><name><surname>Santangelo</surname><given-names>F.</given-names></name><name><surname>Li Volsi</surname><given-names>G.</given-names></name><name><surname>Ciranna</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus.</article-title>
<source/><italic>Hippocampus</italic>
<volume>19</volume>
<fpage>99</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20488</pub-id>
<pub-id pub-id-type="pmid">18727050</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>L.</given-names></name><name><surname>Sardone</surname><given-names>L. M.</given-names></name><name><surname>Bonaccorso</surname><given-names>C. M.</given-names></name><name><surname>D’Antoni</surname><given-names>S.</given-names></name><name><surname>Spatuzza</surname><given-names>M.</given-names></name><name><surname>Gulisano</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Activation of serotonin 5-HT7 receptors modulates hippocampal synaptic plasticity by stimulation of adenylate cyclases and rescues learning and behavior in a mouse model of fragile X syndrome.</article-title>
<source/><italic>Front. Mol. Neurosci.</italic>
<volume>11</volume>:<issue>353</issue>. <pub-id pub-id-type="doi">10.3389/fnmol.2018.00353</pub-id>
<pub-id pub-id-type="pmid">30333723</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>L.</given-names></name><name><surname>Sardone</surname><given-names>L. M.</given-names></name><name><surname>Lacivita</surname><given-names>E.</given-names></name><name><surname>Leopoldo</surname><given-names>M.</given-names></name><name><surname>Ciranna</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome.</article-title>
<source/><italic>Front. Behav. Neurosci.</italic>
<volume>9</volume>:<issue>65</issue>. <pub-id pub-id-type="doi">10.3389/fnbeh.2015.00065</pub-id>
<pub-id pub-id-type="pmid">25814945</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>L.</given-names></name><name><surname>Spatuzza</surname><given-names>M.</given-names></name><name><surname>D’Antoni</surname><given-names>S.</given-names></name><name><surname>Bonaccorso</surname><given-names>C. M.</given-names></name><name><surname>Trovato</surname><given-names>C.</given-names></name><name><surname>Musumeci</surname><given-names>S. A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>72</volume>
<fpage>924</fpage>–<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.06.008</pub-id>
<pub-id pub-id-type="pmid">22817866</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>J. C.</given-names></name><name><surname>Klann</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>The translation of translational control by FMRP: therapeutic targets for FXS.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>16</volume>
<fpage>1530</fpage>–<lpage>1536</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3379</pub-id>
<pub-id pub-id-type="pmid">23584741</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deguil</surname><given-names>J.</given-names></name><name><surname>Chavant</surname><given-names>F.</given-names></name><name><surname>Lafay-Chebassier</surname><given-names>C.</given-names></name><name><surname>Perault-Pochat</surname><given-names>M. C.</given-names></name><name><surname>Fauconneau</surname><given-names>B.</given-names></name><name><surname>Pain</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice.</article-title>
<source/><italic>Neuro. Res.</italic>
<volume>17</volume>
<fpage>142</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-009-9091-4</pub-id>
<pub-id pub-id-type="pmid">19626386</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejda</surname><given-names>A.</given-names></name><name><surname>Seaborn</surname><given-names>T.</given-names></name><name><surname>Bourgault</surname><given-names>S.</given-names></name><name><surname>Touzani</surname><given-names>O.</given-names></name><name><surname>Fournier</surname><given-names>A.</given-names></name><name><surname>Vaudry</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action.</article-title>
<source/><italic>Peptides</italic>
<volume>32</volume>
<fpage>1207</fpage>–<lpage>1216</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2011.04.003</pub-id>
<pub-id pub-id-type="pmid">21514338</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Mauro</surname><given-names>M.</given-names></name><name><surname>Cavallaro</surname><given-names>S.</given-names></name><name><surname>Ciranna</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide modifies the electrical activity of CA1 hippocampal neurons in the rat.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>337</volume>
<fpage>97</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3940(02)01316-2</pub-id>
<pub-id pub-id-type="pmid">12527397</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>L.</given-names></name><name><surname>Finlayson</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>VPAC and PAC receptors: from ligands to function.</article-title>
<source/><italic>Pharmacol. Ther.</italic>
<volume>121</volume>
<fpage>294</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.11.006</pub-id>
<pub-id pub-id-type="pmid">19109992</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doan</surname><given-names>N. D.</given-names></name><name><surname>Bourgault</surname><given-names>S.</given-names></name><name><surname>Dejda</surname><given-names>A.</given-names></name><name><surname>Letourneau</surname><given-names>M.</given-names></name><name><surname>Detheux</surname><given-names>M.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>81</volume>
<fpage>552</fpage>–<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2010.11.015</pub-id>
<pub-id pub-id-type="pmid">21114961</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doberer</surname><given-names>D.</given-names></name><name><surname>Gschwandtner</surname><given-names>M.</given-names></name><name><surname>Mosgoeller</surname><given-names>W.</given-names></name><name><surname>Bieglmayer</surname><given-names>C.</given-names></name><name><surname>Heinzl</surname><given-names>H.</given-names></name><name><surname>Petkov</surname><given-names>V.</given-names></name></person-group> (<year>2007</year>). <article-title>Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects.</article-title>
<source/><italic>Eur. J. Clin. Invest</italic>
<volume>37</volume>
<fpage>665</fpage>–<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2362.2007.01832.x</pub-id>
<pub-id pub-id-type="pmid">17635578</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogrukol-Ak</surname><given-names>D.</given-names></name><name><surname>Kumar</surname><given-names>V. B.</given-names></name><name><surname>Ryerse</surname><given-names>J. S.</given-names></name><name><surname>Farr</surname><given-names>S. A.</given-names></name><name><surname>Verma</surname><given-names>S.</given-names></name><name><surname>Nonaka</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models.</article-title>
<source/><italic>J. Cereb. Blood Flow Metab.</italic>
<volume>29</volume>
<fpage>411</fpage>–<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2008.131</pub-id>
<pub-id pub-id-type="pmid">19002200</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufes</surname><given-names>C.</given-names></name><name><surname>Gaillard</surname><given-names>F.</given-names></name><name><surname>Uchegbu</surname><given-names>I. F.</given-names></name><name><surname>Schatzlein</surname><given-names>A. G.</given-names></name><name><surname>Olivier</surname><given-names>J. C.</given-names></name><name><surname>Muller</surname><given-names>J. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.</article-title>
<source/><italic>Int. J. Pharm.</italic>
<volume>285</volume>
<fpage>77</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2004.07.020</pub-id>
<pub-id pub-id-type="pmid">15488681</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farnham</surname><given-names>M. M.</given-names></name><name><surname>Lung</surname><given-names>M. S.</given-names></name><name><surname>Tallapragada</surname><given-names>V. J.</given-names></name><name><surname>Pilowsky</surname><given-names>P. M.</given-names></name></person-group> (<year>2012</year>). <article-title>PACAP causes PAC1/VPAC2 receptor mediated hypertension and sympathoexcitation in normal and hypertensive rats.</article-title>
<source/><italic>Am. J. Physiol. Heart Circ. Physiol.</italic>
<volume>303</volume>
<fpage>H910</fpage>–<lpage>H917</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00464.2012</pub-id>
<pub-id pub-id-type="pmid">22886412</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feher</surname><given-names>M.</given-names></name><name><surname>Gaszner</surname><given-names>B.</given-names></name><name><surname>Tamas</surname><given-names>A.</given-names></name><name><surname>Gil-Martinez</surname><given-names>A. L.</given-names></name><name><surname>Fernandez-Villalba</surname><given-names>E.</given-names></name><name><surname>Herrero</surname><given-names>M. T.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Alteration of the PAC1 receptor expression in the basal ganglia of MPTP-induced parkinsonian macaque monkeys.</article-title>
<source/><italic>Neuro. Res.</italic>
<volume>33</volume>
<fpage>702</fpage>–<lpage>715</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-017-9841-7</pub-id>
<pub-id pub-id-type="pmid">29230633</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>K.</given-names></name><name><surname>Smith</surname><given-names>K. T.</given-names></name><name><surname>Reines</surname><given-names>D.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Transcription, translation and fragile X syndrome.</article-title>
<source/><italic>Curr. Opin. Genet. Dev.</italic>
<volume>16</volume>
<fpage>270</fpage>–<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2006.04.010</pub-id>
<pub-id pub-id-type="pmid">16647847</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanizada</surname><given-names>H.</given-names></name><name><surname>Al-Karagholi</surname><given-names>M. A.</given-names></name><name><surname>Arngrim</surname><given-names>N.</given-names></name><name><surname>Ghanizada</surname><given-names>M.</given-names></name><name><surname>Larsson</surname><given-names>H. B. W.</given-names></name><name><surname>Amin</surname><given-names>F. M.</given-names></name><etal></etal></person-group> (<year>2019a</year>). <article-title>Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: a 3T MRI study.</article-title>
<source/><italic>Peptides</italic>
<volume>121</volume>:<issue>170134</issue>. <pub-id pub-id-type="doi">10.1016/j.peptides.2019.170134</pub-id>
<pub-id pub-id-type="pmid">31449829</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanizada</surname><given-names>H.</given-names></name><name><surname>Al-Karagholi</surname><given-names>M. A.</given-names></name><name><surname>Arngrim</surname><given-names>N.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name></person-group> (<year>2019b</year>). <article-title>PACAP27 induces migraine-like attacks in migraine patients.</article-title>
<source/><italic>Cephalalgia</italic>
<volume>12</volume>:<issue>333102419864507</issue>. <pub-id pub-id-type="doi">10.1177/0333102419864507</pub-id>
<pub-id pub-id-type="pmid">31299857</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuffrida</surname><given-names>R.</given-names></name><name><surname>Musumeci</surname><given-names>S.</given-names></name><name><surname>D’Antoni</surname><given-names>S.</given-names></name><name><surname>Bonaccorso</surname><given-names>C. M.</given-names></name><name><surname>Giuffrida-Stella</surname><given-names>A. M.</given-names></name><name><surname>Oostra</surname><given-names>B. A.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>25</volume>
<fpage>8908</fpage>–<lpage>8916</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.0932-05.2005</pub-id>
<pub-id pub-id-type="pmid">16192381</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gocel</surname><given-names>J.</given-names></name><name><surname>Larson</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Synaptic NMDA receptor-mediated currents in anterior piriform cortex are reduced in the adult fragile X mouse.</article-title>
<source/><italic>Neuroscience</italic>
<volume>221</volume>
<fpage>170</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.06.052</pub-id>
<pub-id pub-id-type="pmid">22750206</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Hoffmann</surname><given-names>A.</given-names></name><name><surname>Bassell</surname><given-names>G. J.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Therapeutic strategies in fragile X syndrome: from bench to bedside and back.</article-title>
<source/><italic>Neurotherapeutics</italic>
<volume>12</volume>
<fpage>584</fpage>–<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-015-0355-9</pub-id>
<pub-id pub-id-type="pmid">25986746</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulisano</surname><given-names>W.</given-names></name><name><surname>Tropea</surname><given-names>M. R.</given-names></name><name><surname>Arancio</surname><given-names>O.</given-names></name><name><surname>Palmeri</surname><given-names>A.</given-names></name><name><surname>Puzzo</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer’s disease.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>138</volume>
<fpage>151</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.06.002</pub-id>
<pub-id pub-id-type="pmid">29885420</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>R. P.</given-names></name><name><surname>Kadunganattil</surname><given-names>S.</given-names></name><name><surname>Shepherd</surname><given-names>A. J.</given-names></name><name><surname>Merrill</surname><given-names>R.</given-names></name><name><surname>Planer</surname><given-names>W.</given-names></name><name><surname>Bruchas</surname><given-names>M. R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Convergent phosphomodulation of the major neuronal dendritic potassium channel Kv4.2 by pituitary adenylate cyclase-activating polypeptide.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>101</volume>
<fpage>291</fpage>–<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.006</pub-id>
<pub-id pub-id-type="pmid">26456351</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagerman</surname><given-names>R. J.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Hazlett</surname><given-names>H. C.</given-names></name><name><surname>Bailey</surname><given-names>D.B.</given-names><suffix>Jr.</suffix></name><name><surname>Moine</surname><given-names>H.</given-names></name><name><surname>Kooy</surname><given-names>R. F.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Fragile X syndrome.</article-title>
<source/><italic>Nat. Rev. Dis. Primers</italic>
<volume>3</volume>:<issue>17065</issue>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.65</pub-id>
<pub-id pub-id-type="pmid">28960184</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Caselli</surname><given-names>R. J.</given-names></name><name><surname>Baxter</surname><given-names>L.</given-names></name><name><surname>Serrano</surname><given-names>G.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Beach</surname><given-names>T. G.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.</article-title>
<source/><italic>JAMA Neurol.</italic>
<volume>72</volume>
<fpage>333</fpage>–<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2014.3625</pub-id>
<pub-id pub-id-type="pmid">25599520</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Baxter</surname><given-names>L. C.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Beach</surname><given-names>T. G.</given-names></name><etal></etal></person-group> (<year>2014a</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease.</article-title>
<source/><italic>Neurology</italic>
<volume>82</volume>
<fpage>1724</fpage>–<lpage>1728</lpage>.<pub-id pub-id-type="pmid">24719484</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Maalouf</surname><given-names>M.</given-names></name><name><surname>Beach</surname><given-names>T. G.</given-names></name><name><surname>Reiman</surname><given-names>E. M.</given-names></name><etal></etal></person-group> (<year>2014b</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide protects against beta-amyloid toxicity.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>35</volume>
<fpage>2064</fpage>–<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.03.022</pub-id>
<pub-id pub-id-type="pmid">24726470</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Nielsen</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Permenter</surname><given-names>M. R.</given-names></name><name><surname>Vogt</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The impact of aging on brain pituitary adenylate cyclase activating polypeptide, pathology and cognition in mice and rhesus macaques.</article-title>
<source/><italic>Front. Aging Neurosci.</italic>
<volume>9</volume>:<issue>180</issue>. <pub-id pub-id-type="doi">10.3389/fnagi.2017.00180</pub-id>
<pub-id pub-id-type="pmid">28659785</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmar</surname><given-names>A. J.</given-names></name><name><surname>Fahrenkrug</surname><given-names>J.</given-names></name><name><surname>Gozes</surname><given-names>I.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name><name><surname>May</surname><given-names>V.</given-names></name><name><surname>Pisegna</surname><given-names>J. R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>166</volume>
<fpage>4</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01871.x</pub-id>
<pub-id pub-id-type="pmid">22289055</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Hashimoto</surname><given-names>H.</given-names></name><name><surname>Shintani</surname><given-names>N.</given-names></name><name><surname>Chiba</surname><given-names>S.</given-names></name><name><surname>Hattori</surname><given-names>S.</given-names></name><name><surname>Okada</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>12</volume>
<fpage>1026</fpage>–<lpage>1032</lpage>.<pub-id pub-id-type="pmid">17387318</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayata-Takano</surname><given-names>A.</given-names></name><name><surname>Kamo</surname><given-names>T.</given-names></name><name><surname>Kijima</surname><given-names>H.</given-names></name><name><surname>Seiriki</surname><given-names>K.</given-names></name><name><surname>Ogata</surname><given-names>K.</given-names></name><name><surname>Ago</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide modulates dendritic spine maturation and morphogenesis via microRNA-132 upregulation.</article-title>
<source/><italic>J. Neurosci</italic>.
<volume>39</volume>
<fpage>4208</fpage>–<lpage>4220</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2468-18.2019</pub-id>
<pub-id pub-id-type="pmid">30886013</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Contractor</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>The developmental switch in GABA polarity is delayed in fragile X mice.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>34</volume>
<fpage>446</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4447-13.2014</pub-id>
<pub-id pub-id-type="pmid">24403144</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirabayashi</surname><given-names>T.</given-names></name><name><surname>Nakamachi</surname><given-names>T.</given-names></name><name><surname>Shioda</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Discovery of PACAP and its receptors in the brain.</article-title>
<source/><italic>J. Headache Pain</italic>
<volume>19</volume>:<issue>28</issue>. <pub-id pub-id-type="doi">10.1186/s10194-018-0855-1</pub-id>
<pub-id pub-id-type="pmid">29619773</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>P. R.</given-names></name><name><surname>Barloese</surname><given-names>M.</given-names></name><name><surname>Fahrenkrug</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>PACAP in hypothalamic regulation of sleep and circadian rhythm: importance for headache.</article-title>
<source/><italic>J. Headache Pain</italic>
<volume>19</volume>:<issue>20</issue>. <pub-id pub-id-type="doi">10.1186/s10194-018-0844-4</pub-id>
<pub-id pub-id-type="pmid">29508090</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Gallagher</surname><given-names>S. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Altered synaptic plasticity in a mouse model of fragile X mental retardation.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>99</volume>
<fpage>7746</fpage>–<lpage>7750</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.122205699</pub-id>
<pub-id pub-id-type="pmid">12032354</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Klann</surname><given-names>E.</given-names></name><name><surname>Costa-Mattioli</surname><given-names>M.</given-names></name><name><surname>Zukin</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Dysregulation of mammalian target of rapamycin signaling in mouse models of autism.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>35</volume>
<fpage>13836</fpage>–<lpage>13842</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2656-15.2015</pub-id>
<pub-id pub-id-type="pmid">26468183</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>S. A.</given-names></name><name><surname>Galvez</surname><given-names>R.</given-names></name><name><surname>Greenough</surname><given-names>W. T.</given-names></name></person-group> (<year>2000</year>). <article-title>Dendritic spine structural anomalies in fragile-X mental retardation syndrome.</article-title>
<source/><italic>Cereb. Cortex</italic>
<volume>10</volume>
<fpage>1038</fpage>–<lpage>1044</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/10.10.1038</pub-id>
<pub-id pub-id-type="pmid">11007554</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquemont</surname><given-names>S.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Hagerman</surname><given-names>R.</given-names></name><name><surname>von Raison</surname><given-names>F.</given-names></name><name><surname>Gasparini</surname><given-names>F.</given-names></name><name><surname>Apostol</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The challenges of clinical trials in fragile X syndrome.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>231</volume>
<fpage>1237</fpage>–<lpage>1250</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-013-3289-0</pub-id>
<pub-id pub-id-type="pmid">24173622</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaworski</surname><given-names>D. M.</given-names></name><name><surname>Proctor</surname><given-names>M. D.</given-names></name></person-group> (<year>2000</year>). <article-title>Developmental regulation of pituitary adenylate cyclase-activating polypeptide and PAC(1) receptor mRNA expression in the rat central nervous system.</article-title>
<source/><italic>Brain Res. Dev. Brain Res.</italic>
<volume>120</volume>
<fpage>27</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-3806(99)00192-3</pub-id>
<pub-id pub-id-type="pmid">10727727</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolivel</surname><given-names>V.</given-names></name><name><surname>Basille</surname><given-names>M.</given-names></name><name><surname>Aubert</surname><given-names>N.</given-names></name><name><surname>de Jouffrey</surname><given-names>S.</given-names></name><name><surname>Ancian</surname><given-names>P.</given-names></name><name><surname>Le Bigot</surname><given-names>J. F.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates.</article-title>
<source/><italic>Neuroscience</italic>
<volume>160</volume>
<fpage>434</fpage>–<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.02.028</pub-id>
<pub-id pub-id-type="pmid">19236905</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>K. M.</given-names></name><name><surname>Chung</surname><given-names>Y. H.</given-names></name><name><surname>Kim</surname><given-names>M. K.</given-names></name><name><surname>Nam</surname><given-names>R. H.</given-names></name><name><surname>Lee</surname><given-names>B. L.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.</article-title>
<source/><italic>J. Comp. Neurol.</italic>
<volume>476</volume>
<fpage>388</fpage>–<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1002/cne.20231</pub-id>
<pub-id pub-id-type="pmid">15282712</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>D. J.</given-names></name><name><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name><surname>Lahvis</surname><given-names>G. P.</given-names></name><name><surname>Yin</surname><given-names>J. C.</given-names></name><name><surname>Malter</surname><given-names>J.</given-names></name><name><surname>Davidson</surname><given-names>R. J.</given-names></name></person-group> (<year>2008</year>). <article-title>The cyclic AMP phenotype of fragile X and autism.</article-title>
<source/><italic>Neurosci. Biobehav. Rev.</italic>
<volume>32</volume>
<fpage>1533</fpage>–<lpage>1543</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.06.005</pub-id>
<pub-id pub-id-type="pmid">18601949</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>M. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.</article-title>
<source/><italic>Cell Signal</italic>
<volume>42</volume>
<fpage>281</fpage>–<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2017.11.004</pub-id>
<pub-id pub-id-type="pmid">29175000</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Markham</surname><given-names>J. A.</given-names></name><name><surname>Weiler</surname><given-names>I. J.</given-names></name><name><surname>Greenough</surname><given-names>W. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>105</volume>
<fpage>4429</fpage>–<lpage>4434</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0800257105</pub-id>
<pub-id pub-id-type="pmid">18332424</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinhult</surname><given-names>J.</given-names></name><name><surname>Adner</surname><given-names>M.</given-names></name><name><surname>Uddman</surname><given-names>R.</given-names></name><name><surname>Cardell</surname><given-names>L. O.</given-names></name></person-group> (<year>2003</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide, effects in the human nose.</article-title>
<source/><italic>Clin. Exp. Allergy</italic>
<volume>33</volume>
<fpage>942</fpage>–<lpage>949</lpage>. <pub-id pub-id-type="pmid">12859451</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojro</surname><given-names>E.</given-names></name><name><surname>Postina</surname><given-names>R.</given-names></name><name><surname>Buro</surname><given-names>C.</given-names></name><name><surname>Meiringer</surname><given-names>C.</given-names></name><name><surname>Gehrig-Burger</surname><given-names>K.</given-names></name><name><surname>Fahrenholz</surname><given-names>F.</given-names></name></person-group> (<year>2006</year>). <article-title>The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein.</article-title>
<source/><italic>FASEB J.</italic>
<volume>20</volume>
<fpage>512</fpage>–<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1096/fj.05-4812fje</pub-id>
<pub-id pub-id-type="pmid">16401644</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Tominaga</surname><given-names>T.</given-names></name><name><surname>Ichikawa</surname><given-names>M.</given-names></name><name><surname>Iijima</surname><given-names>T.</given-names></name></person-group> (<year>1997</year>). <article-title>Differential alteration of hippocampal synaptic strength induced by pituitary adenylate cyclase activating polypeptide-38 (PACAP-38).</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>221</volume>
<fpage>189</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3940(96)13323-1</pub-id>
<pub-id pub-id-type="pmid">9121696</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkmaz</surname><given-names>O. T.</given-names></name><name><surname>Ay</surname><given-names>H.</given-names></name><name><surname>Aytan</surname><given-names>N.</given-names></name><name><surname>Carreras</surname><given-names>I.</given-names></name><name><surname>Kowall</surname><given-names>N. W.</given-names></name><name><surname>Dedeoglu</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Vasoactive intestinal peptide decreases beta-amyloid accumulation and prevents brain atrophy in the 5xFAD mouse model of Alzheimer’s Disease.</article-title>
<source/><italic>J. Mol. Neurosci</italic>.
<volume>68</volume>
<fpage>389</fpage>–<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-018-1226-8</pub-id>
<pub-id pub-id-type="pmid">30498985</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkmaz</surname><given-names>O. T.</given-names></name><name><surname>Tuncel</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Advantages of vasoactive intestinal peptide for the future treatment of Parkinson’s Disease.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<volume>24</volume>
<fpage>4693</fpage>–<lpage>4701</lpage>. <pub-id pub-id-type="doi">10.2174/1381612825666190111150953</pub-id>
<pub-id pub-id-type="pmid">30636594</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koves</surname><given-names>K.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Gorcs</surname><given-names>T. G.</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A.</given-names></name></person-group> (<year>1991</year>). <article-title>Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain.</article-title>
<source/><italic>Neuroendocrinology</italic>
<volume>54</volume>
<fpage>159</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1159/000125864</pub-id>
<pub-id pub-id-type="pmid">1766552</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladjimi</surname><given-names>M. H.</given-names></name><name><surname>Barbouche</surname><given-names>R.</given-names></name><name><surname>Ben Barka</surname><given-names>Z.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><name><surname>Lefranc</surname><given-names>B.</given-names></name><name><surname>Leprince</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Comparison of the effects of PACAP-38 and its analog, acetyl-[Ala(15), Ala(20)] PACAP-38-propylamide, on spatial memory, post-learning BDNF expression and oxidative stress in rat.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>359</volume>
<fpage>247</fpage>–<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2018.10.023</pub-id>
<pub-id pub-id-type="pmid">30343054</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamine</surname><given-names>A.</given-names></name><name><surname>Letourneau</surname><given-names>M.</given-names></name><name><surname>Doan</surname><given-names>N. D.</given-names></name><name><surname>Maucotel</surname><given-names>J.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Vaudry</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced <italic>in vivo</italic> cardiovascular side effects in a Parkinson’s disease model.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>108</volume>
<fpage>440</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.014</pub-id>
<pub-id pub-id-type="pmid">26006268</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamine-Ajili</surname><given-names>A.</given-names></name><name><surname>Fahmy</surname><given-names>A. M.</given-names></name><name><surname>Letourneau</surname><given-names>M.</given-names></name><name><surname>Chatenet</surname><given-names>D.</given-names></name><name><surname>Labonte</surname><given-names>P.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in <italic>in vitro</italic> and <italic>in vivo</italic> models of Parkinson’s disease.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1862</volume>
<fpage>688</fpage>–<lpage>695</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.01.005</pub-id>
<pub-id pub-id-type="pmid">26769362</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Geng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>J. Q.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name></person-group> (<year>2003</year>). <article-title>Frequency modulation of synchronized Ca2+ spikes in cultured hippocampal networks through G-protein-coupled receptors.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>23</volume>
<fpage>4156</fpage>–<lpage>4163</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.23-10-04156.2003</pub-id>
<pub-id pub-id-type="pmid">12764103</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>D. S.</given-names></name><name><surname>Weerapura</surname><given-names>M.</given-names></name><name><surname>Beazely</surname><given-names>M. A.</given-names></name><name><surname>Martin</surname><given-names>L.</given-names></name><name><surname>Czerwinski</surname><given-names>W.</given-names></name><name><surname>Roder</surname><given-names>J. C.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>25</volume>
<fpage>11374</fpage>–<lpage>11384</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.3871-05.2005</pub-id>
<pub-id pub-id-type="pmid">16339032</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>B. S.</given-names></name><name><surname>Corbin</surname><given-names>J. G.</given-names></name><name><surname>Huntsman</surname><given-names>M. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala.</article-title>
<source/><italic>J. Neurophysiol.</italic>
<volume>112</volume>
<fpage>890</fpage>–<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00597.2013</pub-id>
<pub-id pub-id-type="pmid">24848467</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzagalli</surname><given-names>R.</given-names></name><name><surname>Leggio</surname><given-names>G. M.</given-names></name><name><surname>Bucolo</surname><given-names>C.</given-names></name><name><surname>Pricoco</surname><given-names>E.</given-names></name><name><surname>Keay</surname><given-names>K. A.</given-names></name><name><surname>Cardile</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Genetic blockade of the dopamine D3 receptor enhances hippocampal expression of PACAP and receptors and alters their cortical distribution.</article-title>
<source/><italic>Neuroscience</italic>
<volume>316</volume>
<fpage>279</fpage>–<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.12.034</pub-id>
<pub-id pub-id-type="pmid">26718601</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuo</surname><given-names>Y.</given-names></name><name><surname>Matsumoto</surname><given-names>Y.</given-names></name><name><surname>Tokito</surname><given-names>F.</given-names></name><name><surname>Tsuda</surname><given-names>M.</given-names></name><name><surname>Fujino</surname><given-names>M.</given-names></name></person-group> (<year>1993</year>). <article-title>Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis.</article-title>
<source/><italic>Brain Res.</italic>
<volume>611</volume>
<fpage>207</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(93)90504-g</pub-id>
<pub-id pub-id-type="pmid">8334515</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Matsumoto</surname><given-names>A.</given-names></name><name><surname>Hashimoto</surname><given-names>H.</given-names></name><name><surname>Shintani</surname><given-names>N.</given-names></name><name><surname>Baba</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice.</article-title>
<source/><italic>Neuroreport</italic>
<volume>14</volume>
<fpage>2095</fpage>–<lpage>2098</lpage>. <pub-id pub-id-type="doi">10.1097/00001756-200311140-00017</pub-id>
<pub-id pub-id-type="pmid">14600504</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurin</surname><given-names>T.</given-names></name><name><surname>Lebrigand</surname><given-names>K.</given-names></name><name><surname>Castagnola</surname><given-names>S.</given-names></name><name><surname>Paquet</surname><given-names>A.</given-names></name><name><surname>Jarjat</surname><given-names>M.</given-names></name><name><surname>Popa</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018a</year>). <article-title>HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<volume>46</volume>
<fpage>6344</fpage>–<lpage>6355</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky267</pub-id>
<pub-id pub-id-type="pmid">29668986</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurin</surname><given-names>T.</given-names></name><name><surname>Melancia</surname><given-names>F.</given-names></name><name><surname>Jarjat</surname><given-names>M.</given-names></name><name><surname>Castro</surname><given-names>L.</given-names></name><name><surname>Costa</surname><given-names>L.</given-names></name><name><surname>Delhaye</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2018b</year>). <article-title>Involvement of phosphodiesterase 2A activity in the pathophysiology of fragile X syndrome.</article-title>
<source/><italic>Cereb. Cortex</italic>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">30137253</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurin</surname><given-names>T.</given-names></name><name><surname>Zongaro</surname><given-names>S.</given-names></name><name><surname>Bardoni</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Fragile X syndrome: from molecular pathology to therapy.</article-title>
<source/><italic>Neurosci. Biobehav. Rev.</italic>
<volume>46(Pt 2)</volume>, <fpage>242</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.01.006</pub-id>
<pub-id pub-id-type="pmid">24462888</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloni</surname><given-names>E. G.</given-names></name><name><surname>Kaye</surname><given-names>K. T.</given-names></name><name><surname>Venkataraman</surname><given-names>A.</given-names></name><name><surname>Carlezon</surname><given-names>W. A.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2018</year>). <article-title>PACAP increases Arc/Arg 3.1 expression within the extended amygdala after fear conditioning in rats.</article-title>
<source/><italic>Neurobiol. Learn Mem.</italic>
<volume>157</volume>
<fpage>24</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2018.11.011</pub-id>
<pub-id pub-id-type="pmid">30458282</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloni</surname><given-names>E. G.</given-names></name><name><surname>Venkataraman</surname><given-names>A.</given-names></name><name><surname>Donahue</surname><given-names>R. J.</given-names></name><name><surname>Carlezon</surname><given-names>W. A.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2016</year>). <article-title>Bi-directional effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on fear-related behavior and c-Fos expression after fear conditioning in rats.</article-title>
<source/><italic>Psychoneuroendocrinology</italic>
<volume>64</volume>
<fpage>12</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.11.003</pub-id>
<pub-id pub-id-type="pmid">26590791</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>W. W.</given-names></name><name><surname>Yuskaitis</surname><given-names>C. J.</given-names></name><name><surname>Yan</surname><given-names>Q.</given-names></name><name><surname>Sikorski</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Jope</surname><given-names>R. S.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>56</volume>
<fpage>463</fpage>–<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.09.017</pub-id>
<pub-id pub-id-type="pmid">18952114</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>A.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Dahl</surname><given-names>R. R.</given-names></name><name><surname>Minamino</surname><given-names>N.</given-names></name><name><surname>Uehara</surname><given-names>A.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>1989</year>). <article-title>Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>164</volume>
<fpage>567</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291x(89)91757-9</pub-id>
<pub-id pub-id-type="pmid">2803320</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>N.</given-names></name><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Mizushima</surname><given-names>H.</given-names></name><name><surname>Shioda</surname><given-names>S.</given-names></name><name><surname>Morley</surname><given-names>J. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Regional differences in PACAP transport across the blood-brain barrier in mice: a possible influence of strain, amyloid beta protein, and age.</article-title>
<source/><italic>Peptides</italic>
<volume>23</volume>
<fpage>2197</fpage>–<lpage>2202</lpage>. <pub-id pub-id-type="doi">10.1016/s0196-9781(02)00248-6</pub-id>
<pub-id pub-id-type="pmid">12535699</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>N.</given-names></name><name><surname>Farr</surname><given-names>S. A.</given-names></name><name><surname>Nakamachi</surname><given-names>T.</given-names></name><name><surname>Morley</surname><given-names>J. E.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Shioda</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.</article-title>
<source/><italic>Peptides</italic>
<volume>36</volume>
<fpage>168</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2012.05.021</pub-id>
<pub-id pub-id-type="pmid">22687366</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>K.</given-names></name><name><surname>Shintani</surname><given-names>N.</given-names></name><name><surname>Hayata-Takano</surname><given-names>A.</given-names></name><name><surname>Kamo</surname><given-names>T.</given-names></name><name><surname>Higashi</surname><given-names>S.</given-names></name><name><surname>Seiriki</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>PACAP enhances axon outgrowth in cultured hippocampal neurons to a comparable extent as BDNF.</article-title>
<source/><italic>PLoS One</italic>
<volume>10</volume>:<issue>e0120526</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0120526</pub-id>
<pub-id pub-id-type="pmid">25807538</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterweil</surname><given-names>E. K.</given-names></name><name><surname>Krueger</surname><given-names>D. D.</given-names></name><name><surname>Reinhold</surname><given-names>K.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2010</year>). <article-title>Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>30</volume>
<fpage>15616</fpage>–<lpage>15627</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3888-10.2010</pub-id>
<pub-id pub-id-type="pmid">21084617</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>C.</given-names></name><name><surname>Kovalchuk</surname><given-names>Y.</given-names></name><name><surname>Wolfer</surname><given-names>D. P.</given-names></name><name><surname>Gass</surname><given-names>P.</given-names></name><name><surname>Martin</surname><given-names>M.</given-names></name><name><surname>Zuschratter</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>21</volume>
<fpage>5520</fpage>–<lpage>5527</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.21-15-05520.2001</pub-id>
<pub-id pub-id-type="pmid">11466423</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecoraro</surname><given-names>V.</given-names></name><name><surname>Sardone</surname><given-names>L. M.</given-names></name><name><surname>Chisari</surname><given-names>M.</given-names></name><name><surname>Licata</surname><given-names>F.</given-names></name><name><surname>Li Volsi</surname><given-names>G.</given-names></name><name><surname>Perciavalle</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>A subnanomolar concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) pre-synaptically modulates glutamatergic transmission in the rat hippocampus acting through acetylcholine.</article-title>
<source/><italic>Neuroscience</italic>
<volume>340</volume>
<fpage>551</fpage>–<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.10.061</pub-id>
<pub-id pub-id-type="pmid">27816700</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirger</surname><given-names>Z.</given-names></name><name><surname>Naskar</surname><given-names>S.</given-names></name><name><surname>Laszlo</surname><given-names>Z.</given-names></name><name><surname>Kemenes</surname><given-names>G.</given-names></name><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Kemenes</surname><given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>Reversal of age-related learning deficiency by the vertebrate PACAP and IGF-1 in a novel invertebrate model of aging: the pond snail (Lymnaea stagnalis).</article-title>
<source/><italic>J. Gerontol. A Biol. Sci. Med. Sci.</italic>
<volume>69</volume>
<fpage>1331</fpage>–<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/glu068</pub-id>
<pub-id pub-id-type="pmid">24846768</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prickaerts</surname><given-names>J.</given-names></name><name><surname>Heckman</surname><given-names>P. R. A.</given-names></name><name><surname>Blokland</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease.</article-title>
<source/><italic>Exp. Opin. Invest. Drugs</italic>
<volume>26</volume>
<fpage>1033</fpage>–<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.1080/13543784.2017.1364360</pub-id>
<pub-id pub-id-type="pmid">28772081</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rat</surname><given-names>D.</given-names></name><name><surname>Schmitt</surname><given-names>U.</given-names></name><name><surname>Tippmann</surname><given-names>F.</given-names></name><name><surname>Dewachter</surname><given-names>I.</given-names></name><name><surname>Theunis</surname><given-names>C.</given-names></name><name><surname>Wieczerzak</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice.</article-title>
<source/><italic>FASEB J.</italic>
<volume>25</volume>
<fpage>3208</fpage>–<lpage>3218</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-180133</pub-id>
<pub-id pub-id-type="pmid">21593432</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Atlasz</surname><given-names>T.</given-names></name><name><surname>Jungling</surname><given-names>A.</given-names></name><name><surname>Szabo</surname><given-names>E.</given-names></name><name><surname>Kovari</surname><given-names>P.</given-names></name><name><surname>Manavalan</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2018a</year>). <article-title>Alternative routes of administration of the neuroprotective pituitary adenylate cyclase activating polypeptide.</article-title>
<source/><italic>Curr. Pharm Des.</italic>
<volume>24</volume>
<fpage>3892</fpage>–<lpage>3904</lpage>. <pub-id pub-id-type="doi">10.2174/1381612824666181112110934</pub-id>
<pub-id pub-id-type="pmid">30417775</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Atlasz</surname><given-names>T.</given-names></name><name><surname>Szabo</surname><given-names>E.</given-names></name><name><surname>Jungling</surname><given-names>A.</given-names></name><name><surname>Tamas</surname><given-names>A.</given-names></name><name><surname>Juhasz</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2018b</year>). <article-title>PACAP deficiency as a model of aging.</article-title>
<source/><italic>Geroscience</italic>
<volume>40</volume>
<fpage>437</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-018-0045-8</pub-id>
<pub-id pub-id-type="pmid">30345481</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Vaczy</surname><given-names>A.</given-names></name><name><surname>Rubio-Beltran</surname><given-names>E.</given-names></name><name><surname>MaassenVanDenBrink</surname><given-names>A.</given-names></name></person-group> (<year>2018c</year>). <article-title>Protective effects of PACAP in ischemia.</article-title>
<source/><italic>J. Headache Pain</italic>
<volume>19</volume>:<issue>19</issue>. <pub-id pub-id-type="doi">10.1186/s10194-018-0845-3</pub-id>
<pub-id pub-id-type="pmid">29500688</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Lubics</surname><given-names>A.</given-names></name><name><surname>Tamas</surname><given-names>A.</given-names></name><name><surname>Szalontay</surname><given-names>L.</given-names></name><name><surname>Lengvari</surname><given-names>I.</given-names></name></person-group> (<year>2004</year>). <article-title>Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson’s disease.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>151</volume>
<fpage>303</fpage>–<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2003.09.007</pub-id>
<pub-id pub-id-type="pmid">15084446</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Renaud</surname><given-names>J.</given-names></name><name><surname>Tamas</surname><given-names>A.</given-names></name><name><surname>Tizabi</surname><given-names>Y.</given-names></name><name><surname>Socias</surname><given-names>S. B.</given-names></name><name><surname>Del-Bel</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>155</volume>
<fpage>120</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.10.004</pub-id>
<pub-id pub-id-type="pmid">26542398</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D.</given-names></name><name><surname>Tamas</surname><given-names>A.</given-names></name><name><surname>Lengvari</surname><given-names>I.</given-names></name><name><surname>Toth</surname><given-names>G.</given-names></name><name><surname>Szalontay</surname><given-names>L.</given-names></name><name><surname>Lubics</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson’s disease.</article-title>
<source/><italic>Ann. N. Y. Acad. Sci.</italic>
<volume>1070</volume>
<fpage>518</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1317.072</pub-id>
<pub-id pub-id-type="pmid">16888218</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhea</surname><given-names>E. M.</given-names></name><name><surname>Bullock</surname><given-names>K. M.</given-names></name><name><surname>Banks</surname><given-names>W. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Effect of controlled cortical impact on the passage of pituitary adenylate cyclase activating polypeptide (PACAP) across the blood-brain barrier.</article-title>
<source/><italic>Peptides</italic>
<volume>99</volume>
<fpage>8</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2017.10.013</pub-id>
<pub-id pub-id-type="pmid">29107653</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberto</surname><given-names>M.</given-names></name><name><surname>Brunelli</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>PACAP-38 enhances excitatory synaptic transmission in the rat hippocampal CA1 region.</article-title>
<source/><italic>Learn Mem.</italic>
<volume>7</volume>
<fpage>303</fpage>–<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1101/lm.34200</pub-id>
<pub-id pub-id-type="pmid">11040262</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberto</surname><given-names>M.</given-names></name><name><surname>Scuri</surname><given-names>R.</given-names></name><name><surname>Brunelli</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region.</article-title>
<source/><italic>Learn Mem.</italic>
<volume>8</volume>
<fpage>265</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1101/lm.40501</pub-id>
<pub-id pub-id-type="pmid">11584073</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runcie</surname><given-names>M. J.</given-names></name><name><surname>Ulman</surname><given-names>L. G.</given-names></name><name><surname>Potter</surname><given-names>E. K.</given-names></name></person-group> (<year>1995</year>). <article-title>Effects of pituitary adenylate cyclase-activating polypeptide on cardiovascular and respiratory responses in anaesthetised dogs.</article-title>
<source/><italic>Regul. Pept.</italic>
<volume>60</volume>
<fpage>193</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/0167-0115(95)00131-x</pub-id>
<pub-id pub-id-type="pmid">8746546</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saavedra</surname><given-names>A.</given-names></name><name><surname>Giralt</surname><given-names>A.</given-names></name><name><surname>Arumi</surname><given-names>H.</given-names></name><name><surname>Alberch</surname><given-names>J.</given-names></name><name><surname>Perez-Navarro</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington’s disease.</article-title>
<source/><italic>PloS One</italic>
<volume>8</volume>:<issue>e73664</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0073664</pub-id>
<pub-id pub-id-type="pmid">24040016</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchetti</surname><given-names>B.</given-names></name><name><surname>Lorenzini</surname><given-names>C. A.</given-names></name><name><surname>Baldi</surname><given-names>E.</given-names></name><name><surname>Bucherelli</surname><given-names>C.</given-names></name><name><surname>Roberto</surname><given-names>M.</given-names></name><name><surname>Tassoni</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat.</article-title>
<source/><italic>Neurobiol. Learn. Mem.</italic>
<volume>76</volume>
<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1006/nlme.2001.4014</pub-id>
<pub-id pub-id-type="pmid">11525248</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M. R.</given-names></name><name><surname>Bray</surname><given-names>S. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Molecular mechanisms of fragile X syndrome: a twenty-year perspective.</article-title>
<source/><italic>Annu. Rev. Pathol.</italic>
<volume>7</volume>
<fpage>219</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132457</pub-id>
<pub-id pub-id-type="pmid">22017584</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauvage</surname><given-names>M.</given-names></name><name><surname>Brabet</surname><given-names>P.</given-names></name><name><surname>Holsboer</surname><given-names>F.</given-names></name><name><surname>Bockaert</surname><given-names>J.</given-names></name><name><surname>Steckler</surname><given-names>T.</given-names></name></person-group> (<year>2000</year>). <article-title>Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks.</article-title>
<source/><italic>Brain Res. Mol. Brain Res.</italic>
<volume>84</volume>
<fpage>79</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-328x(00)00219-9</pub-id>
<pub-id pub-id-type="pmid">11113534</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S. D.</given-names></name><name><surname>Myskiw</surname><given-names>J. C.</given-names></name><name><surname>Furini</surname><given-names>C. R.</given-names></name><name><surname>Schmidt</surname><given-names>B. E.</given-names></name><name><surname>Cavalcante</surname><given-names>L. E.</given-names></name><name><surname>Izquierdo</surname><given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>PACAP modulates the consolidation and extinction of the contextual fear conditioning through NMDA receptors.</article-title>
<source/><italic>Neurobiol. Learn. Mem.</italic>
<volume>118</volume>
<fpage>120</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2014.11.014</pub-id>
<pub-id pub-id-type="pmid">25490058</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>H. W.</given-names></name><name><surname>Birk</surname><given-names>S.</given-names></name><name><surname>Wienecke</surname><given-names>T.</given-names></name><name><surname>Kruuse</surname><given-names>C.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>PACAP38 induces migraine-like attacks in patients with migraine without aura.</article-title>
<source/><italic>Brain</italic>
<volume>132</volume>
<fpage>16</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awn307</pub-id>
<pub-id pub-id-type="pmid">19052139</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekar</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Chow</surname><given-names>B. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Central control of feeding behavior by the secretin, PACAP, and glucagon family of peptides.</article-title>
<source/><italic>Front. Endocrinol.</italic>
<volume>8</volume>:<issue>18</issue>. <pub-id pub-id-type="doi">10.3389/fendo.2017.00018</pub-id>
<pub-id pub-id-type="pmid">30057570</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethna</surname><given-names>F.</given-names></name><name><surname>Moon</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>From FMRP function to potential therapies for fragile X syndrome.</article-title>
<source/><italic>Neurochem. Res.</italic>
<volume>39</volume>
<fpage>1016</fpage>–<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-013-1229-3</pub-id>
<pub-id pub-id-type="pmid">24346713</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Hoeffer</surname><given-names>C. A.</given-names></name><name><surname>Takayasu</surname><given-names>Y.</given-names></name><name><surname>Miyawaki</surname><given-names>T.</given-names></name><name><surname>McBride</surname><given-names>S. M.</given-names></name><name><surname>Klann</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Dysregulation of mTOR signaling in fragile X syndrome.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>30</volume>
<fpage>694</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3696-09.2010</pub-id>
<pub-id pub-id-type="pmid">20071534</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shioda</surname><given-names>S.</given-names></name><name><surname>Nakamachi</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>PACAP as a neuroprotective factor in ischemic neuronal injuries.</article-title>
<source/><italic>Peptides</italic>
<volume>72</volume>
<fpage>202</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2015.08.006</pub-id>
<pub-id pub-id-type="pmid">26275482</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shioda</surname><given-names>S.</given-names></name><name><surname>Shuto</surname><given-names>Y.</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A.</given-names></name><name><surname>Legradi</surname><given-names>G.</given-names></name><name><surname>Onda</surname><given-names>H.</given-names></name><name><surname>Coy</surname><given-names>D. H.</given-names></name><etal></etal></person-group> (<year>1997</year>). <article-title>Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain.</article-title>
<source/><italic>Neurosci. Res.</italic>
<volume>28</volume>
<fpage>345</fpage>–<lpage>354</lpage>. <pub-id pub-id-type="pmid">9274830</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivers</surname><given-names>K. Y.</given-names></name><name><surname>Nikolopoulou</surname><given-names>A.</given-names></name><name><surname>Machlovi</surname><given-names>S. I.</given-names></name><name><surname>Vallabhajosula</surname><given-names>S.</given-names></name><name><surname>Figueiredo-Pereira</surname><given-names>M. E.</given-names></name></person-group> (<year>2014</year>). <article-title>PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1842</volume>
<fpage>1707</fpage>–<lpage>1719</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.06.020</pub-id>
<pub-id pub-id-type="pmid">24970746</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ster</surname><given-names>J.</given-names></name><name><surname>de Bock</surname><given-names>F.</given-names></name><name><surname>Bertaso</surname><given-names>F.</given-names></name><name><surname>Abitbol</surname><given-names>K.</given-names></name><name><surname>Daniel</surname><given-names>H.</given-names></name><name><surname>Bockaert</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Epac mediates PACAP-dependent long-term depression in the hippocampus.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>587</volume>
<fpage>101</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2008.157461</pub-id>
<pub-id pub-id-type="pmid">19001039</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takuma</surname><given-names>K.</given-names></name><name><surname>Maeda</surname><given-names>Y.</given-names></name><name><surname>Ago</surname><given-names>Y.</given-names></name><name><surname>Ishihama</surname><given-names>T.</given-names></name><name><surname>Takemoto</surname><given-names>K.</given-names></name><name><surname>Nakagawa</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>An enriched environment ameliorates memory impairments in PACAP-deficient mice.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>272</volume>
<fpage>269</fpage>–<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2014.07.005</pub-id>
<pub-id pub-id-type="pmid">25014004</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C. L.</given-names></name><name><surname>Cooke</surname><given-names>E. K.</given-names></name><name><surname>Leib</surname><given-names>D. E.</given-names></name><name><surname>Lin</surname><given-names>Y. C.</given-names></name><name><surname>Daly</surname><given-names>G. E.</given-names></name><name><surname>Zimmerman</surname><given-names>C. A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Warm-sensitive neurons that control body temperature.</article-title>
<source/><italic>Cell</italic>
<volume>167</volume>:<issue>e15</issue>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.08.028</pub-id>
<pub-id pub-id-type="pmid">27616062</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R. D.</given-names></name><name><surname>Madsen</surname><given-names>M. G.</given-names></name><name><surname>Krause</surname><given-names>M.</given-names></name><name><surname>Sampedro-Castaneda</surname><given-names>M.</given-names></name><name><surname>Stocker</surname><given-names>M.</given-names></name><name><surname>Pedarzani</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide (PACAP) inhibits the slow afterhyperpolarizing current sIAHP in CA1 pyramidal neurons by activating multiple signaling pathways.</article-title>
<source/><italic>Hippocampus</italic>
<volume>24</volume>
<fpage>32</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.22201</pub-id>
<pub-id pub-id-type="pmid">23996525</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>A. M.</given-names></name><name><surname>Huganir</surname><given-names>R. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Regulation of AMPA receptor phosphorylation by the neuropeptide PACAP38.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>112</volume>
<fpage>6712</fpage>–<lpage>6717</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1507229112</pub-id>
<pub-id pub-id-type="pmid">25964356</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsumi</surname><given-names>M.</given-names></name><name><surname>Claus</surname><given-names>T. H.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.</article-title>
<source/><italic>Diabetes</italic>
<volume>51</volume>
<fpage>1453</fpage>–<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.51.5.1453</pub-id>
<pub-id pub-id-type="pmid">11978642</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzunova</surname><given-names>G.</given-names></name><name><surname>Hollander</surname><given-names>E.</given-names></name><name><surname>Shepherd</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.</article-title>
<source/><italic>Curr. Neuropharmacol.</italic>
<volume>12</volume>
<fpage>71</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X113116660046</pub-id>
<pub-id pub-id-type="pmid">24533017</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaudry</surname><given-names>D.</given-names></name><name><surname>Falluel-Morel</surname><given-names>A.</given-names></name><name><surname>Bourgault</surname><given-names>S.</given-names></name><name><surname>Basille</surname><given-names>M.</given-names></name><name><surname>Burel</surname><given-names>D.</given-names></name><name><surname>Wurtz</surname><given-names>O.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>61</volume>
<fpage>283</fpage>–<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1124/pr.109.001370</pub-id>
<pub-id pub-id-type="pmid">19805477</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkerk</surname><given-names>A. J.</given-names></name><name><surname>Pieretti</surname><given-names>M.</given-names></name><name><surname>Sutcliffe</surname><given-names>J. S.</given-names></name><name><surname>Fu</surname><given-names>Y. H.</given-names></name><name><surname>Kuhl</surname><given-names>D. P.</given-names></name><name><surname>Pizzuti</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>1991</year>). <article-title>Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.</article-title>
<source/><italic>Cell</italic>
<volume>65</volume>
<fpage>905</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(91)90397-h</pub-id>
<pub-id pub-id-type="pmid">1710175</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>Y. Y.</given-names></name><name><surname>Sun</surname><given-names>X. K.</given-names></name><name><surname>Zhang</surname><given-names>Y. F.</given-names></name><name><surname>Zhou</surname><given-names>H. Y.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Neuroprotective effects of PACAP27 in mice model of Parkinson’s disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum.</article-title>
<source/><italic>Neuropeptides</italic>
<volume>42</volume>
<fpage>267</fpage>–<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2008.03.002</pub-id>
<pub-id pub-id-type="pmid">18440632</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>J. J.</given-names></name><name><surname>Chohan</surname><given-names>M. O.</given-names></name><name><surname>Slifstein</surname><given-names>M.</given-names></name><name><surname>Kegeles</surname><given-names>L. S.</given-names></name><name><surname>Moore</surname><given-names>H.</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Pathway-specific dopamine abnormalities in schizophrenia.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>81</volume>
<fpage>31</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2016.03.2104</pub-id>
<pub-id pub-id-type="pmid">27206569</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z. L.</given-names></name><name><surname>Ciallella</surname><given-names>J. R.</given-names></name><name><surname>Flood</surname><given-names>D. G.</given-names></name><name><surname>O’Kane</surname><given-names>T. M.</given-names></name><name><surname>Bozyczko-Coyne</surname><given-names>D.</given-names></name><name><surname>Savage</surname><given-names>M. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparative analysis of cortical gene expression in mouse models of Alzheimer’s disease.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>27</volume>
<fpage>377</fpage>–<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.02.010</pub-id>
<pub-id pub-id-type="pmid">15927307</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaka</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>D. Y.</given-names></name><name><surname>Phamluong</surname><given-names>K.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>278</volume>
<fpage>9630</fpage>–<lpage>9638</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m209141200</pub-id>
<pub-id pub-id-type="pmid">12524444</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Lei</surname><given-names>G.</given-names></name><name><surname>Jackson</surname><given-names>M. F.</given-names></name><name><surname>Macdonald</surname><given-names>J. F.</given-names></name></person-group> (<year>2010</year>). <article-title>The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus.</article-title>
<source/><italic>J. Mol. Neurosci.</italic>
<volume>42</volume>
<fpage>319</fpage>–<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-010-9372-7</pub-id>
<pub-id pub-id-type="pmid">20414742</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group> (<year>2012a</year>). <article-title>The novel peptide PACAP-TAT with enhanced traversing ability attenuates the severe lung injury induced by repeated smoke inhalation.</article-title>
<source/><italic>Peptides</italic>
<volume>38</volume>
<fpage>142</fpage>–<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2012.09.005</pub-id>
<pub-id pub-id-type="pmid">22982609</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2012b</year>). <article-title>The TAT peptide endows PACAP with an enhanced ability to traverse bio-barriers.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>527</volume>
<fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2012.08.005</pub-id>
<pub-id pub-id-type="pmid">22939769</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>S. H.</given-names></name><name><surname>Trommer</surname><given-names>B. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>89</volume>
<fpage>176</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.22546</pub-id>
<pub-id pub-id-type="pmid">21162125</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>